Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5915
Title: Expression and amplification of topoisomerase-2? in type 1 and type 2 papillary renal cell carcinomas and its correlation with HER2/neu amplification
Authors: Düzcan, Füsun
Duzcan, S.E.
Sen, S.
Yorukoglu, K.
Caner, Vildan
Şen Türk, Nilay
Çetin, Gökhan Ozan
Keywords: FISH
HER2/neu
Immunohistochemistry
Papillary renal cell carcinoma
Topoisomerase-2?
DNA topoisomerase
DNA topoisomerase IIalpha
epidermal growth factor receptor 2
unclassified drug
article
cancer staging
clinical article
clinical feature
controlled study
cytogenetics
fluorescence in situ hybridization
gene amplification
gene dosage
gene overexpression
genetic association
human
human tissue
immunohistochemistry
immunoreactivity
kidney carcinoma
molecular dynamics
morphology
oncogene
papillary renal cell carcinoma type 1
papillary renal cell carcinoma type 2
TOP2alpha gene
Carcinoma, Papillary
Carcinoma, Renal Cell
Chromosomes, Human, Pair 17
DNA Probes
Gene Amplification
Humans
In Situ Hybridization, Fluorescence
Kidney Neoplasms
Neoplasm Grading
Neoplasm Staging
Prognosis
Receptor, erbB-2
Abstract: The current study was undertaken to investigate chromosomal and genetical aberrations leading to overexpression of Topoisomerase-2? (TOP2?) and to reveal the possible association of these aberrations with HER2/neu overexpression and gene amplification, and to search for the relationship between TOP2? and HER2/neu status with prognostical biomarkers in papillary renal cell carcinoma (RCC), a group of tumors with diverse molecular, chromosomal and clinical features. Archival cases of papillary RCC obtained from Departments of Pathology of Pamukkale, Ege and Dokuz Eylul Universities were studied in two groups (type 1 and type 2) each containing 20 cases. The level of TOP2? and HER2/neu expression by tumor cells were determined immunohistochemically. A multicolor FISH probe was used to define both amplification of HER2/neu and TOP2? genes, and polysomy 17. The ratio of cells expressing TOP2? in type 1 and type 2 papillary RCC were 24.29% and 6.89%, respectively. The difference was statistically significant comparing the average or median values of groups separately (p = 0.002). The expression levels of TOP2? and HER2/neu were also correlated. TOP2? and HER2/neu were co-amplified in both groups. Immunohistochemical expression was not observed in 15 of 23 cases with HER2/neu amplification. The most frequent finding detected by FISH method was polysomy of chromosome 17. We had contradictory results compared with the findings reported in the limited numbers of literature. It shows us that papillary RCC constitute a heterogenous group of tumors with various cytogenetic features and morphological classification of these tumors may not be compatible with their molecular characteristics. © 2011 Arányi Lajos Foundation.
URI: https://hdl.handle.net/11499/5915
https://doi.org/10.1007/s12253-011-9372-0
ISSN: 1219-4956
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
0697a.pdf379.7 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

6
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

6
checked on Nov 16, 2024

Page view(s)

68
checked on Aug 24, 2024

Download(s)

20
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.